Skip to main content
SpringerLink
Log in

Should clinical trials about prostate cancer assess the frailty as an endpoint?

  • Urology - Letter to the Editor
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Boyle HJ, Alibhai S, Decoster L, Efstathiou E, Fizazi K, Mottet N et al (2019) Updated recommendations of the international society of geriatric oncology on prostate cancer management in older patients. Eur J Cancer 116:116–136. https://doi.org/10.1016/J.EJCA.2019.04.031

    Article  CAS  PubMed  Google Scholar 

  2. Gluszak C, Campion L, Seegers V, Cojocarasu O, Commer JM, Priou F et al (2023) Geriatric assessment ımplementation before chemotherapy in metastatic prostate cancer, results from the real-life study gamers. J Clin Med. https://doi.org/10.3390/jcm12041636

    Article  PubMed  PubMed Central  Google Scholar 

  3. Dent E, Martin FC, Bergman H, Woo J, Romero-Ortuno R, Walston JD (2019) Management of frailty: opportunities, challenges, and future directions. Lancet (London, England) 394:1376–1386. https://doi.org/10.1016/S0140-6736(19)31785-4

    Article  PubMed  Google Scholar 

  4. Liu X, Sun W (2022) Frailty assessment for outcome prediction of patients with prostate cancer receiving radical prostatectomy: a meta-analysis of cohort studies. Clin Nurs Res 31:1136–1147. https://doi.org/10.1177/10547738221100350

    Article  PubMed  Google Scholar 

  5. Pan YY, Meng LC, Chen HM, Chen LK, Hsiao FY (2022) Impact of frailty on survivals of prostate cancer patients treated with radiotherapy. Arch Gerontol Geriatr 100:104651. https://doi.org/10.1016/j.archger.2022.104651

    Article  CAS  PubMed  Google Scholar 

  6. Bylow K, Mohile SG, Stadler WM, Dale W (2007) Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer? conceptual review Cancer 110:2604–2613. https://doi.org/10.1002/cncr.23084

    Article  CAS  PubMed  Google Scholar 

  7. Cheung AS, Hoermann R, Dupuis P, Joon DL, Zajac JD, Grossmann M (2016) Relationships between insulin resistance and frailty with body composition and testosterone in men undergoing androgen deprivation therapy for prostate cancer. Eur J Endocrinol 175:229–237. https://doi.org/10.1530/EJE-16-0200

    Article  CAS  PubMed  Google Scholar 

  8. Buigues C, Navarro-Martínez R, Sánchez-Martínez V, Serrano-Carrascosa M, Rubio-Briones J, Cauli O (2020) Interleukin-6 and lymphocyte count associated and predicted the progression of frailty syndrome in prostate cancer patients undergoing antiandrogen therapy. Cancers (Basel) 12:1–17. https://doi.org/10.3390/cancers12071716

    Article  CAS  Google Scholar 

  9. Kim VS, Yang H, Timilshina N, Breunis H, Emmenegger U, Gregg R et al (2023) The role of frailty in modifying physical function and quality of life over time in older men with metastatic castration-resistant prostate cancer. J Geriatr Oncol. 14:101417. https://doi.org/10.1016/j.jgo.2022.12.005

    Article  CAS  PubMed  Google Scholar 

  10. Togashi K, Hatakeyama S, Soma O, Okita K, Fujita N, Tanaka T et al (2022) Utility of the age discrepancy between frailty-based biological age and expected life age in patients with urological cancers. Cancers (Basel). https://doi.org/10.3390/cancers14246229

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Ankara Bilkent City Hospital, Ankara, 06800, Turkey

    Irfan Karahan & Didem Sener Dede

  2. Ankara Yildirim Beyazıt University, Ankara, Turkey

    Didem Sener Dede

Authors
  1. Irfan Karahan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Didem Sener Dede
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Irfan Karahan.

Ethics declarations

Conflict of interest

The authors declare there is no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Karahan, I., Dede, D.S. Should clinical trials about prostate cancer assess the frailty as an endpoint?. Int Urol Nephrol 55, 1729–1730 (2023). https://doi.org/10.1007/s11255-023-03636-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-023-03636-8

Search

Navigation